What this means

IL23R receives signals that drive certain immune-cell types (Th17) toward pro-inflammatory responses. The R381Q variant reduces receptor function, damping this pathway. The protective effect across multiple autoimmune conditions inspired the development of IL-23 inhibitor drugs (ustekinumab, guselkumab, risankizumab) now widely used for psoriasis and Crohn's. Carrying the variant doesn't guarantee freedom from these conditions — it just shifts the prior favourably.

IL23R sits on the surface of certain immune cells and helps tell them to ramp up inflammation. The R381Q change makes the receptor work less well, which dials that signal down. People with this change have lower lifetime risk of several inflammatory diseases — Crohn's, ulcerative colitis, psoriasis, and ankylosing spondylitis. That natural protective effect is what inspired a whole class of modern drugs (ustekinumab, guselkumab, risankizumab) that block IL-23 and are now widely used to treat psoriasis and Crohn's. Having this change doesn't guarantee you'll never get these conditions — it just shifts the odds in your favour.

Caveats

• Effect is "protective on average" — does not preclude disease.
• Replicated across multiple ancestry groups, particularly European.
• Knowing this variant doesn't change clinical management.

References

• Duerr et al. — A genome-wide association study identifies IL23R as an inflammatory bowel disease gene (Science, 2006)
• Sivanesan et al. — IL23R protective variant R381Q and immune-mediated diseases (Nature Reviews Rheumatology, 2016)